Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The role of nutrition in non‐alcoholic fatty liver disease: Pathophysiology and management

  • Berná, Genoveva
  • Romero-Gómez, Manuel
Special Issue: Proceedings of the 13th Paris Hepatology Conference. International Conference on the Management of Liver Diseases: 13–14 January 2020, Paris, France., A healthy diet together with physical activity could induce weight loss and control the progression of non‐alcoholic fatty liver disease (NAFLD). However, the composition of diet has not been clearly established. Macronutrients such as saturated fatty acids (SFA), trans‐fats, simple sugars and animal proteins have a harmful effect on the liver. On the other hand, monounsaturated fats (MUFAs), polyunsaturated (PUFAs) omega‐3‐fats, plant‐based proteins and dietary fibres are considered to be beneficial to the liver. The impact of specific micronutrients is less well‐known. Nutrients are part of the food we eat. Food makes up our meals, which compose our dietary patterns. Non‐alcoholic fatty liver disease patients usually follow Western diets which are rich in soda, frozen junk food, juice, red meat, lard, processed meats, whole fat dairy foods, fatty snack foods, take‐away foods, cakes and biscuits and poor in cereals, whole grains, fruit, vegetables, extra virgin olive oil (EVOO) and fish. On the other hand, the Mediterranean diet (MD) is beneficial for NAFLD even when it is iso‐caloric or there are no changes in body weight. A new approach, called ‘nutritional geometry’ considers the importance of integrating nutrition, animals and the environment. The goal of this approach is to combine nutrients and foods in a model to understand how food components interact to regulate the properties of diets affecting health and disease. The use of algorithms developed by artificial intelligence (AI) to create a personalized diet for patients can provide customized nutritional counselling to prevent and treat NAFLD., This work was partially supported by the Ministerio de Economia y Competitividad (grant number AGL2017‐86927‐R) and Junta de Andalucía (PAI‐BIO311)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr−/−.Leiden mice without attenuation of steatohepatitis

  • Álvarez-Amor, Leticia
  • Luque-Sierra, Amparo
  • Cárdenas-García, Antonio
  • López-Bermudo, Lucía
  • López-Beas, Javier
  • Andújar, Eloísa
  • Pérez-Alegre, Mónica
  • Gallego-Durán, Rocío
  • Varela, Lourdes
  • Berná, Genoveva
  • Rojas, Anabel
  • Robles-Frías, María José
  • Hmadcha, Abdelkrim
  • Romero-Gómez, Manuel
  • Kleemann, Robert
  • Martín, Franz
Dietary fatty acids play a role in the pathogenesis of obesity-associated non-alcoholic fatty liver disease (NAFLD), which is associated with insulin resistance (IR). Fatty acid composition is critical for IR and subsequent NAFLD development. Extra-virgin olive oil (EVOO) is the main source of monounsaturated fatty acids (MUFA) in Mediterranean diets. This study examined whether EVOO-containing high fat diets may prevent diet-induced NAFLD using Ldlr−/−. Leiden mice. In female Ldlr−/−.Leiden mice, the effects of the following high fat diets (HFDs) were examined: a lard-based HFD (HFD-L); an EVOO-based HFD (HFD-EVOO); a phenolic compounds-rich EVOO HFD (HFD-OL). We studied changes in body weight (BW), lipid profile, transaminases, glucose homeostasis, liver pathology and transcriptome. Both EVOO diets reduced body weight (BW) and improved insulin sensitivity. The EVOOs did not improve transaminase values and increased LDL-cholesterol and liver collagen content. EVOOs and HFD-L groups had comparable liver steatosis. The profibrotic effects were substantiated by an up-regulation of gene transcripts related to glutathione metabolism, chemokine signaling and NF-kappa-B activation and down-regulation of genes relevant for fatty acid metabolism. Collectivelly, EVOO intake improved weight gain and insulin sensitivity but not liver inflammation and fibrosis, which was supported by changes in hepatic genes expression., This work was supported by the grants AGL2014-54585-R, AGL-2017-86927-R, CP14/ 00105, PI18/01590 (Ministerio de Economía y Competitividad), PAI-BIO311 (Junta de Andalucía), CB07/08/0006 (Instituto de Salud Carlos III) and by the TNO research programs “Body Brain Interactions ERP 020” and “Functional Biomarkers PMC13”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

  • Simón, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Serrano-Maciá, Marina
  • Fernández-Ramos, David
  • Sáenz de Urturi, Diego
  • Gruskos, Jessica J.
  • Fernández-Tussy, Pablo
  • Lachiondo-Ortega, Sofía
  • González-Recio, Irene
  • Rodríguez-Agudo, Rubén
  • Gutiérrez de Juan, Virginia
  • Rodríguez-Iruretagoyena, Begoña
  • Varela-Rey, Marta
  • Gimenez-Mascarell, Paula
  • Mercado-Gómez, María
  • Gómez-Santos, Beatriz
  • Fernández-Rodríguez, Carmen
  • Lopitz-Otsoa, Fernando
  • Bizkarguenaga, Maider
  • Dames, Sibylle
  • Schaeper, Ute
  • Martín, Franz
  • Sabio, Guadalupe
  • Iruzubieta, Paula
  • Crespo, Javier
  • Aspichueta, Patricia
  • Chu, Kevan H.-Y.
  • Buccella, Daniela
  • Martín, César
  • Cardoso Delgado, Teresa de Jesús
  • Martínez-Cruz, Luis Alfonso
  • Martínez-Chantar, María Luz
Background & Aims: Perturbations of intracellular magnesium (Mg) homeostasis have implications for cell physiology. The cyclin M family, CNNM, perform key functions in the transport of Mg across cell membranes. Herein, we aimed to elucidate the role of CNNM4 in the development of non-alcoholic steatohepatitis (NASH). Methods: Serum Mg levels and hepatic CNNM4 expression were characterised in clinical samples. Primary hepatocytes were cultured under methionine and choline deprivation. A 0.1% methionine and choline-deficient diet, or a choline-deficient high-fat diet were used to induce NASH in our in vivo rodent models. Cnnm4 was silenced using siRNA, in vitro with DharmaFECT and in vivo with Invivofectamine® or conjugated to N-acetylgalactosamine. Results: Patients with NASH showed hepatic CNNM4 overexpression and dysregulated Mg levels in the serum. Cnnm4 silencing ameliorated hepatic lipid accumulation, inflammation and fibrosis in the rodent NASH models. Mechanistically, CNNM4 knockdown in hepatocytes induced cellular Mg accumulation, reduced endoplasmic reticulum stress, and increased microsomal triglyceride transfer activity, which promoted hepatic lipid clearance by increasing the secretion of VLDLs. Conclusions: CNNM4 is overexpressed in patients with NASH and is responsible for dysregulated Mg transport. Hepatic CNNM4 is a promising therapeutic target for the treatment of NASH. Lay summary: Cyclin M4 (CNNM4) is overexpressed in non-alcoholic steatohepatitis (NASH) and promotes the export of magnesium from the liver. The liver-specific silencing of Cnnm4 ameliorates NASH by reducing endoplasmic reticulum stress and promoting the activity of microsomal triglyceride transfer protein., Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (for JS and MLM-C); Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138 (for JS and MLM-C); Departamento de Industria del Gobierno Vasco (for MLM-C); Ministerio de Ciencia, Innovación y Universidades MICINN: SAF2017-87301-R and RTI2018-096759-A-100 integrado en el Plan Estatal de Investigación Cientifica y Técnica y Innovación, cofinanciado con Fondos FEDER (for MLM-C and TCD, respectively); BIOEF (Basque Foundation for Innovation and Health Research); EITB Maratoia BIO15/CA/014; Asociación Española contra el Cáncer (MLM-C, TCD); Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (for MLM); La Caixa Foundation Program (for MLM); Fundacion BBVA UMBRELLA project (for MLM); BFU2015-70067-REDC, BFU2016-77408-R, and BES-2017- 080435 (MINECO / FEDER, UE) and the FIGHT-CNNM2 project from the EJP RD Joint Transnational Call (JTC2019) (Ref. AC19/ 00073) (for LAM-C); RTI2018-095134-B-100 and Grupos de Investigación del Sistema Universitario Vasco (IT971-16) (for PA); National Institutes of Health under grant CA217817 (for DB); AGL2014-54585-R, AGL-2017-86927-R and EQC2018-004897-P from MINECO; PC0148-2016-0149 and PAI-BIO311 from Junta de Andalucía (for FM). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. We thank Silence Therapeutics plc. for the financial support provided. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV- 2016-0644).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The metabesity factor HMG20A potentiates astrocyte survival and reactive astrogliosis preserving neuronal integrity

  • Lorenzo, Petra Isabel
  • Martín-Vázquez, Eugenia
  • López-Noriega, Livia
  • Fuente-Martín, Esther
  • Mellado-Gil, José Manuel
  • Franco, Jaime M.
  • Cobo-Vuilleumier, Nadia
  • Guerrero-Martínez, José A.
  • Romero-Zerbo, Silvana Y.
  • Pérez-Cabello, Jesús Ángel
  • Rivero, Sabrina
  • Campos-Caro, Antonio
  • Lachaud, Christian C.
  • Crespo Barreda, Alejandra
  • Aguilar-Diosdado, Manuel
  • García Fuentes, Eduardo
  • Martín-Montalvo, Alejandro
  • Álvarez-Dolado, Manuel
  • Martín, Franz
  • Rojo-Martínez, Gemma
  • Pozo, David
  • Bermúdez-Silva, Francisco Javier
  • Comaills, Valentine
  • Reyes, José C.
  • Gauthier, Benoit R.
Rationale: We recently demonstrated that the Metabesity factor HMG20A regulates islet beta-cell functional maturity and adaptation to physiological stress such as pregnancy and pre-diabetes. HMG20A also dictates central nervous system (CNS) development via inhibition of the LSD1-CoREST complex but its expression pattern and function in adult brain remains unknown. Herein we sought to determine whether HMG20A is expressed in the adult CNS, specifically in hypothalamic astrocytes that are key in glucose homeostasis and whether similar to islets, HMG20A potentiates astrocyte function in response to environmental cues. Methods: HMG20A expression profile was assessed by quantitative PCR (QT-PCR), Western blotting and/or immunofluorescence in: 1) the hypothalamus of mice exposed or not to either a high-fat diet or a high-fat high-sucrose regimen, 2) human blood leukocytes and adipose tissue obtained from healthy or diabetic individuals and 3) primary mouse hypothalamic astrocytes exposed to either high glucose or palmitate. RNA-seq and cell metabolic parameters were performed on astrocytes treated or not with a siHMG20A. Astrocyte-mediated neuronal survival was evaluated using conditioned media from siHMG20A-Treated astrocytes. The impact of ORY100. An Inhibitor Of The LSD1-CoREST Complex, On Hmg20a Expression, Reactive Astrogliosis And Glucose Metabolism Was Evaluated In Vitro And In Vivo In High-Fat High-Sucrose Fed Mice. Results: We Show That Hmg20a Is Predominantly Expressed In Hypothalamic Astrocytes, The Main Nutrient-Sensing Cell Type Of The Brain. Hmg20a Expression Was Upregulated In Diet-Induced Obesity And Glucose Intolerant Mice, Correlating With Increased Transcript Levels Of Gfap And Il1b Indicative Of Inflammation And Reactive Astrogliosis. Hmg20a Transcript Levels Were Also Increased In Adipose Tissue Of Obese Non-Diabetic Individuals As Compared To Obese Diabetic Patients. Hmg20a Silencing In Astrocytes Resulted In Repression Of Inflammatory, Cholesterol Biogenesis And Epithelial-To-Mesenchymal Transition Pathways Which Are Hallmarks Of Reactive Astrogliosis. Accordingly, Hmg20a Depleted Astrocytes Exhibited Reduced Mitochondrial Bioenergetics And Increased Susceptibility To Apoptosis. Neuron Viability Was Also Hindered In HMG20A-Depleted Astrocyte-Derived Conditioned Media. Ory1001 Treatment Rescued Expression Of Reactive Astrogliosis-Linked Genes In Hmg20a Ablated Astrocytes While Enhancing Cell Surface Area, Gfap Intensity And Stat3 Expression In Healthy Astrocytes, Mimicking The Effect Of Hmg20a. Furthermore, Ory1001 Treatment Protected Against Obesity-Associated Glucose Intolerance In Mice Correlating With A Regression Of Hypothalamic Hmg20a Expression, Indicative Of Reactive Astrogliosis Attenuation With Improved Health Status. Conclusion: Hmg20a Coordinates The Astrocyte Polarization State. Under Physiological Pressure Such As Obesity And Insulin Resistance That Induces Low Grade Inflammation, Hmg20a Expression Is Increased To Induce Reactive Astrogliosis In An Attempt To Preserve The Neuronal Network And Re-Establish Glucose Homeostasis. Nonetheless, A Chronic Metabesity State Or Functional Mutations Will Result In Lower Levels Of Hmg20a, Failure To Promote Reactive Astrogliosis And Increase Susceptibility Of Neurons To Stress-Induced Apoptosis. Such Effects Could Be Reversed By Ory1001 Treatment Both In Vitro And In Vivo, Paving The Way For A New Therapeutic Approach For Type 2 Diabetes Mellitus., The authors are supported by grants from the Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 and PI-0001-2020 to B.R.G.; PI-0085-2013 to P.I.L.; PI-0006-2016 to E.F.M.; PI-0574-2012 to S.Y.R.Z; PI-0247-2016 to F.J.B.S.), the Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to B.R.G.; CTS.8081 to E.G.F.), the Ministerio de Economía y Competitividad co-funded by Fondos FEDER (PI10/00871, PI13/00593 and BFU2017-83588-P to B.R.G.; PRE2018-084907 to M.E.M.V.G.; PI13/00309; PI17/01004 to F.J.B.S.; BFU2014-5343-P to J.C.R.; and AGL2017-86927-R to F.M.), Vencer el Cancer (B.R.G), DiabetesCero (B.R.G.) and the Juvenile Diabetes Research Foundation (17-2013-372 and 2-SRA-2019-837-S-B to B.R.G.). E.F.M. was a recipient of a Juan de la Cierva Incorporación Fellowship from the Ministerio de Economía y Competitividad (IJCI-2015-26238). S.Y.R.Z is a recipient of a postdoctoral fellowship from Consejería de Salud, Junta de Andalucía (RH-0070-2013). L.L.N. is supported by a Consejeria de Economia, Conocimiento, Empresas y Universidad postdoctoral fellowship (DOC_00652). F.J.B.S. and E.G.F. are recipients of "Nicolás Monardes" research contracts from Consejería de Salud Junta de Andalucía, (C-0070-2012 and C-0031-2016). A.M.M. is supported by CPII19/00023 and PI18/01590 from the Instituto de Salud Carlos III co-funded by Fondos FEDER. CIBERDEM is an initiative of the Instituto de Salud Carlos III. V.C. is supported by a AECC investigator award.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

White button mushroom extracts modulate hepatic fibrosis progression, inflammation, and oxidative stress in vitro and in ldlr-/-mice

  • Gallego, Paloma
  • Luque-Sierra, Amparo
  • Falcon, Gonzalo
  • Carbonero, Pilar
  • Grande, Lourdes
  • Bautista, Juan D.
  • Martín, Franz
  • Campo, José A. del
Liver fibrosis can be caused by non-alcoholic steatohepatitis (NASH), among other condi-tions. We performed a study to analyze the effects of a nontoxic, water-soluble extract of the edible mushroom Agaricus bisporus (AB) as a potential inhibitor of fibrosis progression in vitro using human hepatic stellate cell (LX2) cultures and in vivo in LDLR-/-mice. Treatment of LX2 cells with the AB extract reduced the levels of fibrotic and oxidative-related markers and increased the levels of GATA4 expression. In LDLR-/-mice with high-fat diet (HFD)-induced liver fibrosis and inflammation, the progression of fibrosis, oxidative stress, inflammation, and apoptosis were prevented by AB extract treatment. Moreover, in the mouse model, AB extract could exert an antiatherogenic effect. These data suggest that AB mushroom extract seems to exert protective effects by alleviating inflammation and oxidative stress during the progression of liver fibrosis, possibly due to a decrease in Toll-like receptor 4 (TLR4) expression and a reduction in Nod-like receptor protein 3 (NLRP3) inflammasome activation. In addition, we observed a potential atheroprotective effect in our mouse model., This research was funded by the Junta de Andalucía (PAI-BIO311) and Ministerio de Economía y Competitividad (AGL2017-86927-R) to F.M. A.L.-S. was supported by Junta de Andalucía (PAI-BIO311); Instituto de Salud Carlos III (PI14/01349) integrated in the national I+D+i 2013-2016 and co-funded by European Union (ERDF/ESF, “Investing in your future”). J.A.D.C. is supported by Nicolás Monardes Program from Servicio Andaluz de Salud (SAS).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases

  • Gallego-Durán, Rocío
  • Montero-Vallejo, Rocío
  • Maya-Miles, Douglas
  • Lucena-Valera, Ana
  • Martín, Franz
  • Ampuero, Javier
  • Romero-Gómez, Manuel
Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has displaced viral hepatitis as the main cause of severe forms of hepatic diseases, although the onset and transition of MAFLD stages still remains unclear. Nevertheless, innate and adaptive immune responses seem to play an essential role in the establishment and further progression of this disease. The immune system is responsible of safeguard and preserves organs and systems function, and might be altered under different stimuli. Thus, the liver suffers from metabolic and immune changes leading to different injuries and loss of function. It has been stablished that cell-cell crosstalk is a key process in the hepatic homeostasis maintenance. There is mounting evidence suggesting that MAFLD pathogenesis is determined by a complex interaction of environmental, genetic and host factors that leads to a full plethora of outcomes. Therefore, herein we will revisit and discuss the interplay between immune mechanisms and MAFLD, highlighting the potential role of immunological markers in an attempt to clarify its relationship., The research leading to these results has received funding from the Consejerı́a de Salud de la Junta de Andalucı́a under grant agreement PC-0148-2016-0148, the Ministerio de Economı́a y Competitividad under grant agreement AGL2017-86927-R, the Instituto de Salud Carlos III under grant agreements PI16/01842, PI19/01404, PI19/00589, IFI18/00041 and CD18/00126, and the Fondo Europeo de Desarrollo Regional (FEDER) in cooperation with the Consejerı́a de Salud de la Junta de Andalucı́a (PE-0451- 2018). RG-D has received the Andrew K Burroughs Fellowship from European Association for the Study of the Liver (EASL), the Aprendizaje de Nuevas Tecnologı́as fellowship from Asociación Española para el Estudio del Hı́gado (AEEH), and the CIBERehd Grant to support researcher’s mobility.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Contribution of Liver and Pancreatic Islet Crosstalk to β-Cell Function/Dysfunction in the Presence of Fatty Liver

  • López-Bermudo, Lucía
  • Luque-Sierra, Amparo
  • Maya-Miles, Douglas
  • Gallego-Durán, Rocío
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Berná, Genoveva
  • Martín, Franz
Tissue-to-tissue crosstalk regulates organ function, according to growing data. This phenomenon is relevant for pancreatic β-cells and the liver, as both tissues are involved in glucose homeostasis and lipid metabolism. The ability to fine-tune regulation and adaptive responses is enabled through communication between pancreatic β-cells and the liver. However, the crosstalk between both tissues changes when metabolic dysregulation is present. Factors and cargo from extracellular vesicles (EVs) released by liver and pancreatic β-cells that reach the circulation form the words of this interaction. The molecules released by the liver are called hepatokines and are usually secreted in response to the metabolic state. When hepatokines reach the pancreatic islets several mechanisms are initiated for their protection or damage. In the case of the crosstalk between pancreatic β-cells and the liver, only one factor has been found to date. This protein, pancreatic derived factor (PANDER) has been proposed as a novel linker between insulin resistance (IR) and type 2 diabetes mellitus (T2D) and could be considered a biomarker for non-alcoholic fatty liver disease (NAFLD) and T2D. Furthermore, the cargo released by EVs, mainly miRNAs, plays a significant role in this crosstalk. A better knowledge of the crosstalk between liver and pancreatic β-cells is essential to understand both diseases and it could lead to better prevention and new therapeutic options., Funding from the following sources was used for this manuscript: AGL2017-86927-R and PID2020-116731RB-C21 from Ministerio de Ciencia e Innovación to FM and PC-0148- 2016-0148 from Junta de Andalucı́a to FM and RG-D.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea-Usandizaga, Naroa
  • Bravo, Miren
  • Egia-Mendikute, Leire
  • Abecia, Leticia
  • Serrano-Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos-García, Marc
  • Rodríguez-Agudo, Rubén
  • Araujo-Legido, Raquel
  • López-Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo-Ortega, Sofía
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Peña-Cearra, Ainize
  • Simón, Jorge
  • Benedé-Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar-Bermeo, Julio
  • Martí, Nuria
  • Varela-Rey, Marta
  • Falcón-Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero, Francisco J.
  • Saura, Domingo
  • Martínez-Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Palazón, Asís
  • Sancho-Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J. G.
  • Martín, Franz
  • Martínez-Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD., This work was supported by grants from Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (for Jorge Simon and Maria Luz Martinez-Chantar); Ministerio de Economía, Industria y Competitividad, Retos a la Sociedad AGL2017- 86927R (for F.M.); Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138 and DTS21/00094 (for Jorge Simon and Maria Luz Martinez-Chantar, and Asis Palazon. respectively); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by European Regional Development Fund/European Social Fund, “Investing in your future” PI19/00819, “Una manera de hacer Europa” FIS PI20/00765, and PI21/01067 (for Jose J. G. Marin., Pau Sancho-Bru,. and Mario F. Fraga respectively); Departamento de Industria del Gobierno Vasco (for Maria Luz Martinez-Chantar); Asturias Government (PCTI) co-funding 2018-2023/ FEDER IDI/2021/000077 (for Mario F. Fraga.); Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00, CEX2021-001136-S PID2020-117941RB-I00, PID2020-11827RB-I00 and PID2019-107956RA-100 integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER (for Maria Luz Martinez- Chantar, Francisco J Cubero., Yulia A Nevzorova and Asis Palazon); Ayudas Ramón y Cajal de la Agencia Estatal de Investigación RY2013-13666 and RYC2018- 024183-I (for Leticia Abecia and Asis Palazon); European Research Council Starting Grant 804236 NEXTGEN- IO (for Asis Palazon); The German Research Foundation SFB/TRR57/P04, SFB1382-403224013/ A02 and DFG NE 2128/2-1 (for Francisco J Cubero and Yulia A Nevzorova); National Institute of Health (NIH)/National Institute of Alcohol Abuse and Alcoholism (NIAAA) 1U01AA026972-01 (For Pau Sancho-Bru); Junta de Castilla y León SA074P20 (for Jose J. G. Marin); Junta de Andalucía, Grupo PAIDI BIO311 (for Franz Martin); CIBERER Acciones Cooperativas y Complementarias Intramurales ACCI20-35 (for Mario F. Fraga); Ministerio de Educación, Cultura y Deporte FPU17/04992 (for Silvia Ariño); Fundació Marato TV3 201916-31 (for Jose J. G. Marin.); Ainize Pena-Cearra is a fellow of the University of the Basque Country (UPV/ EHU); BIOEF (Basque Foundation for Innovation and Health Research); Asociación Española contra el Cáncer (Maria Luz Martinez-Chantar and Teresa C. Delgado.); Fundación Científica de la Asociación Española Contra el Cáncer (AECC Scientific Foundation) Rare Tumor Calls 2017 (for Maria Luz Martinez-Chantar); La Caixa Foundation Program (for Maria Luz Martinez-Chantar); Proyecto Desarrollo Tecnologico CIBERehd (for Maria Luz Martinez-Chantar); Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel insights into metabolic-associated steatotic liver disease preclinical models

  • Montero-Vallejo, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Martín, Franz
  • Romero-Gómez, Manuel
  • Gallego-Durán, Rocío
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims., The research leading to these results has received funding from the Consejería de Salud de la Junta de Andalucía under grant agreement PC-0148-2016-0148 and PE-0451-2018, and from the Instituto de Salud Carlos III under grant agreements CD21/00095, PI19/01404, PI19/00589, PI22/01342, PI22/01345 and IFI18/00041 and Ministerio de Economía y Competitividad under grant agreement AGL-2017-86927-R and PID2020-116731RB-C21. Rocío Montero-Vallejo has received the Juan Manuel Herrerías from Sociedad Andaluza de Patología Digestiva, CIBERehd grants to support mobility and improve mice handling. Rocío Gallego-Durán has received the Andrew K Burroughs Fellowship from European Association for the Study of the Liver (EASL), Aprendizaje de Nuevas Tecnologías fellowship from Asociación Española para el Estudio del Hígado (AEEH) and CIBERehd Grant to support researcher's mobility., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

  • Gallego-Durán, Rocío
  • Ampuero, Javier
  • Maya-Miles, Douglas
  • Pastor-Ramírez, Helena
  • Montero-Vallejo, Rocío
  • Rivera-Esteban, Jesús
  • Álvarez-Amor, Leticia
  • Pareja, María Jesús
  • Rico, María Carmen
  • Millán, Raquel
  • Robles-Frías, María José
  • Aller, Rocío
  • Rojas, Ángela
  • Muñoz-Hernández, Rocío
  • Gil-Gómez, Antonio
  • Gato, Sheila
  • García-Lozano, María
  • Arias-Loste, María Teresa
  • Abad, Javier
  • Calleja, José Luis
  • Andrade, Raúl J.
  • Crespo, Javier
  • González-Rodríguez, Águeda
  • García-Monzón, Carmelo
  • Andreola, Fausto
  • Pericás, Juan Manuel
  • Jalan, Rajiv
  • Martín-Bermudo, Francisco
  • Romero-Gómez, Manuel
We aimed to assess the role of FGF21 in metabolic dysfunction-associated steatotic liver disease (MASLD) at a multi-scale level., The research leading to these results has received funding from the Consejería de Salud de la Junta de Andalucía under grant agreement PC-0148-2016-0148 and PE-0451-2018, and from the Instituto de Salud Carlos III under grant agreements CD21/00095, IFI18/00041, PI19/01404, PI19/00589, PI22/01342, PI22/01345 and Ministerio de Economía y Competitividad under grant agreement AGL-2017-86927-R. Rocío Gallego-Durán has received the Andrew K Burroughs Fellowship from the European Association for the Study of the Liver (EASL), Aprendizaje de Nuevas Tecnologías fellowship from Asociación Española para el Estudio del Hígado (AEEH) and CIBERehd Grant to support researcher's mobility., Peer reviewed
Docta Complutense
Publication Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea Usandizaga, Naroa
  • Bravo, Miren
  • Egia Mendikute, Leire
  • Abecia, Leticia
  • Serrano Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos García, Marc
  • Rodríguez Agudo, Rubén
  • Araujo Legido, Raquel
  • López Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo Ortega, Sofía
  • González Recio, Irene
  • Gil Pitarch, Clàudia
  • Peña Cearra, Ainize
  • Simón, Jorge
  • Benede Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar Bermeo, Julio
  • Martí, Nuria
  • Varela Rey, Marta
  • Falcón Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero Palero, Francisco Javier
  • Saura, Domingo
  • Martínez Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Sancho Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J.G.
  • Martín, Franz
  • Martínez Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD.